ClinicalTrials.gg
CompletedNCT06916897EDG-5506-102Updated Apr 8, 2025

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

A Phase 1 interventional study of sevasemten and Verapamil in Healthy Subjects, sponsored by Edgewise Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Edgewise Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purposes of this Phase 1 study of sevasemten are to:

  1. Evaluate the effect of multiple-dose administration of verapamil on the single-dose of sevasemten in healthy adults
  2. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without verapamil in healthy adult subjects.
  3. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without food in healthy adult subjects.
02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Edgewise Therapeutics, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, adult, male or female (of non-)18-60 years of age, inclusive, at the screening visit.
  2. Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing based on subject self-reporting.
  3. (BMI) ≥ 18.0 and \< 30.0 kg/m2 at the screening visit.
  4. Medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, or ECGs.
  5. Willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
  2. History or presence of alcohol or drug abuse (except for use of cannabis products) within the past 2 years prior to first dosing.
  3. Female subjects of .
  4. Alcohol consumption > 14 drinks per week for males or ˃ 7 drinks for females within 45 days prior to the screening visit.
  5. Positive results for (HIV), surface antigen (HBsAg), or virus (HCV) at the screening visit.
  6. Any drugs known to be moderate or strong inducers of enzymes/or P glycoprotein, including St. John's Wort, beginning 28 days prior to the first dosing.
  7. Is lactose intolerant.
  8. Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to first dosing, whichever is longer.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Treatment A: single dose sevasemten

    Single dose sevasemten administered on Day 1 under fasting conditions

    Drug: sevasemten

  • Experimental
    Treatment B: multiple doses of verapamil and single dose of sevasemten

    Multiple doses of verapamil with a single dose of sevasemten under fasting conditions

    Drug: sevasemten · Drug: Verapamil

  • Experimental
    Treatment C: single dose sevasemten and high-fat meal

    Single dose sevasemten under high-fat fed conditions

    Drug: sevasemten

Interventions

  • single dose 10mg sevasemten administered orally

  • multiple doses 240mg verapamil

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic

    The area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) for sevasemten and metabolites administered with and without verapamil

    Time frame: Up to 46 days of monitoring

  2. Pharmacokinetic

    The maximum observed concentration (Cmax) for sevasemten and metabolites administered with and without verapamil

    Time frame: Up to 46 days of monitoring

  3. Pharmacokinetic

    The area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) for sevasemten and metabolites under fasting and fed conditions

    Time frame: up to 42 days of monitoring

  4. Pharmacokinetic

    The maximum observed concentration (Cmax) for sevasemten and metabolites under fasting and fed conditions

    Time frame: up to 42 days of monitoring

  5. Pharmacokinetic

    The time to reach the maximum observed concentration (Tmax) for sevasemten and metabolites under fasting and fed conditions

    Time frame: up to 42 days of monitoring

  6. Pharmacokinetic

    The lag time, time delayed between drug administration and the onset of absorption (Tlag), for sevasemten and metabolites under fasting and fed conditions

    Time frame: up to 42 days of monitoring

Secondary outcomes

  1. Safety and Tolerability

    Incidence of treatment emergent adverse events in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  2. Safety and Tolerability

    Incidence of abnormal chemistry test results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  3. Safety and Tolerability

    Incidence of abnormal hematology test results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  4. Safety and Tolerability

    Incidence of abnormal urinalysis test results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  5. Safety and Tolerability

    Incidence of abnormal heart rate results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  6. Safety and Tolerability

    Incidence of abnormal blood pressure results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  7. Safety and Tolerability

    Incidence of abnormal body temperature results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  8. Safety and Tolerability

    Incidence of abnormal respiratory rate results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

  9. Safety and Tolerability

    Incidence of abnormal 12-lead ECG results in those with a single dose of sevasemten administered with and without verapamil and with or without food

    Time frame: Up to 46 days of monitoring

07

Study locations

2 sites
  • Celerion
    Tempe, Arizona 85283, United States
  • Celerion
    Lincoln, Nebraska 68502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Feb 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Apr 8, 2025
StartActual
Jan 8, 2025
Primary completionActual
Feb 22, 2025
CompletionActual
Feb 22, 2025
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06916897
Lead sponsor
Edgewise Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Jan 8, 2025
Primary completion
Feb 22, 2025
Completion
Feb 22, 2025
Last update
Apr 8, 2025

Study contacts

Roxana D Dreghici, MD
study chair · Edgewise Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevasemten

Start the discussion